October 2019 Midatech Pharma PLC ("Midatech" or the "Company") Total Voting Rights Midatech (AIM: MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to

("Midatech" or the "Company")

MTPH.L; Nasdaq: MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients,

announces total voting rights following the closing of its registered direct offering in the US of 3,000,000 American Depositary

Shares (equivalent to 60,000,000 ordinary shares of 0.005 pence each ("New Ordinary Shares").

been made for admission of the 60,000,000 New Ordinary Shares to trading on AIM, which is anticipated to occur at 8:00am on 29

October 2019 ("Admission"). The New Ordinary Shares will rank pari passu with the existing ordinary shares of 0.005

pence each in the Company.

Following Admission,

the Company's issued ordinary share capital will consist of 469,899,613 ordinary shares. The Company does not hold any shares in

treasury. Therefore, the total number of ordinary shares with voting rights in Midatech following Admission will be 469,899,613.

of 469,899,613 may be used by shareholders as the denominator for the calculations by which they will determine if they are required

to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency

For more information, please contact:

Midatech Pharma PLC (dual listed on LSE

AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving delivery of drugs

in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide

compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment

for life threatening diseases.

The Company has developed three in-house

technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's

technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

By improving biodelivery and biodistribution

of approved existing molecules, Midatech's unique R&D has the potential to make medicines better, lower technical risks,

accelerate regulatory approval and route to market, and provide newly patentable products. The platform nature of the technologies

allows the potential to develop multiple drug assets rather than being reliant on a limited number of programmes.

Midatech's headquarters and R&D facility

is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com

in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom

and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate

to matters of historical fact should be considered forward-looking statements.

be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance

with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs")

and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important

factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements.

These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking

statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may

be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake

any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise